Trials / Completed
CompletedNCT04603326
FoxBioNet: ECV (Extracellular Vesicle) 004
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 140 (actual)
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to identify reliable markers of LRRK2 activity in human CSF.
Detailed description
Specific aims of this project are: Primary Objectives: To evaluate each assay performance for its ability to detect LRRK2, its activity and/or the detection and activity of the pathways it impacts using a variety of different approaches (quantitative western blot, immunoassays and LC-MS). Assay performance will be assessed and those demonstrating high sensitivity and consistency will be considered for further development. Secondary Objectives: To assess the ability of the assay or a combination of assays to differentiate pathogenic LRRK2 variant manifesting and non-manifesting carriers, idiopathic PD and healthy non-carriers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Lumbar Puncture | Lumbar Puncture for collection of Cerebrospinal Fluids |
Timeline
- Start date
- 2021-05-06
- Primary completion
- 2023-07-01
- Completion
- 2023-07-01
- First posted
- 2020-10-26
- Last updated
- 2023-10-16
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04603326. Inclusion in this directory is not an endorsement.